Evaluation of CA- 125 as a prognostic marker in patients with Non-Hodgkin’s lymphoma
Journal Title: International Journal of Medical and Health Research - Year 2017, Vol 3, Issue 4
Abstract
Background: Non-Hodgkin lymphoma (NHL) is a heterogeneous group of blood cancers that includes all types of lymphoma except Hodgkin's lymphomas. CA-125 is a protein that in humans is encoded by the MUC16 gene. The present study was conducted to assess the role of CA- 125 in patients suffering from non- Hodgkin lymphoma. Materials &Methods: This study was conducted from year 2011 to 2015 on the patients visiting a tertiary care hospital in north India. It included 110 patients suffering from Non-Hodgkin’s lymphoma. Patients were divided into two groups. Group I with CA-125 level < 35 U/ml and group II with CA-125 level > 35 U/ml. Complete blood count (CBC) and levels of urea, creatinine, calcium, total bilirubin, lactate dehydrogenase (LDH), aspartate transaminase (AST), and alanine transaminase (ALT) were collected. Viral markers such as hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and human T-cell lymphoma virus (HTLV-I) were also evaluated for some of the patients. Serum CA-125 level was measured using chemiluminescence. The International Prognostic Index (IPI) was calculated. Staging of NHL was also assessed. Results: Out of 110 patients, group I (CA- 125 level <35 U/ml) had 60 patients and group II (CA- 125 level >35 U/ml) had 50 patients. Relapse rate in group I and group II was 15.8% and 33.4% respectively. The mortality rate in group I was 10% and in group II was 28%. The difference was significant (P <0.05). Group I had 34 males and 26 females and group II had 28 males and 22 females. The difference was non – significant (P = 0.25). 60% in group I and 25% in group II had low IPI score. 8.5% in group I and 12.6% in group II had high IPI score. The difference was significant (P < 0.05). 55% in group I and 25% in group II had stage I, 33% in group I and 37% in group II had stage II, 10% in group I and 24% in group II had stage III and 2% in group I and 14% in group II had stage IV. The difference was significant (P < 0.05). Conclusion: CA- 125 is a biomarker can be useful in evaluating prognosis in Non Hodgkin lymphoma patients and their response to treatment. It is a cost effective and non-invasive marker.
Authors and Affiliations
Dr. Sanjeev Garg, Dr. Bela Goyal
Keywords
Related Articles
- EP ID EP584922
- DOI -
- Views 141
- Downloads 0
A study on pelvic examination under anesthesia
Introduction:Medical students need to undertake supervised pelvic examinations to achieve competence. This experience is frequently obtained by conducting pelvic examinations on anaesthetized patients who are undergoing...
Retromolar intubation: An alternative to invasive intubation techniques in multiple facial injuries
To evaluate the success and complications of retromolar intubation technique in multiple facial fractures which require maxillo-mandibular fixation (MMF) during the surgical procedure. 11 patients who require treatment f...
Study of fungal load in wards, departments and doctors' equipments in a tertiary care hospital and evaluation of 3 new mounting solutions for fungal micromorphological study
Fungi are very important causes of nosocomial infections. Fungal infections of hospital origin are gaining importance in recently due to their progressive increase and high mortality and morbidity with which they are ass...
Monitoring of febrile urinary tract infection in children
Urinary tract infection (UTI) is an infection that affects part of the urinary tract. When it affects the lower urinary tract it is known as a bladder infection (cystitis) and when it affects the upper urinary tract it i...
Prevalence of pulp exposures during tooth preparation for fixed dental prosthesis
Purpose: The purpose of this study was to record the prevalence of pulp exposures occurring during preparation of vital abutment teeth. Materials and Methods: 2527 patients (1495 female, 1032 male) who received metal-cer...